StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Trading Down 4.2 %
IRIX opened at $1.81 on Friday. The stock has a 50-day moving average of $1.96 and a 200 day moving average of $2.36. IRIDEX has a 12 month low of $1.63 and a 12 month high of $3.65. The firm has a market cap of $29.42 million, a P/E ratio of -2.70 and a beta of 0.78.
IRIDEX (NASDAQ:IRIX – Get Free Report) last released its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.80 million. IRIDEX had a negative net margin of 21.84% and a negative return on equity of 134.37%. During the same period in the prior year, the firm posted ($0.17) EPS. On average, research analysts forecast that IRIDEX will post -0.52 earnings per share for the current fiscal year.
Institutional Trading of IRIDEX
IRIDEX Company Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Articles
- Five stocks we like better than IRIDEX
- Why Invest in High-Yield Dividend Stocks?
- The Average 401k Balance by Age Explained
- What are earnings reports?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Canadian Penny Stocks: Can They Make You Rich?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.